Gyre Therapeutics: Concerns Lurk Beneath Strong Earnings Report

Gyre Therapeutics' (NASDAQ:GYRE) stock price surged after its earnings report, but shareholders may be overlooking some concerns. The company increased shares on issue by 5.9% over the last year, diluting earnings per share. Although Gyre Therapeutics booked a profit this year, its underlying earnings power may be less than its statutory profit.